Login / Signup

Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies.

Sonja FernbachNina K MairIrene A AbelaKevin GroenRoger KuratliMarie LorkChristian W ThorballEnos BernasconiParaskevas FilippidisKaroline LeuzingerJulia NotterAndri RauchHans H HirschMichael HuberHuldrych F GunthardJacques FellayRoger D KouyosBenjamin G Halenull null
Published in: The Journal of experimental medicine (2024)
Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. Here, we trace the development of these autoantibodies at high-resolution using longitudinal samples from 1,876 well-treated individuals living with HIV over a 35-year period. Similar to general populations, ∼1.9% of individuals acquired anti-IFN-I autoantibodies as they aged (median onset ∼63 years). Once detected, anti-IFN-I autoantibodies persisted lifelong, and titers increased over decades. Individuals developed distinct neutralizing and non-neutralizing autoantibody repertoires at discrete times that selectively targeted combinations of IFNα, IFNβ, and IFNω. Emergence of neutralizing anti-IFNα autoantibodies correlated with reduced baseline IFN-stimulated gene levels and was associated with subsequent susceptibility to severe COVID-19 several years later. Retrospective measurements revealed enrichment of pre-existing autoreactivity against other autoantigens in individuals who later developed anti-IFN-I autoantibodies, and there was evidence for prior viral infections or increased IFN at the time of anti-IFN-I autoantibody triggering. These analyses suggest that age-related loss of self-tolerance prior to IFN-I immune-triggering poses a risk of developing lifelong functional IFN-I deficiency.
Keyphrases
  • dendritic cells
  • immune response
  • systemic lupus erythematosus
  • sars cov
  • coronavirus disease
  • gene expression
  • mass spectrometry
  • cross sectional
  • drug delivery
  • cancer therapy
  • single cell